Je veux savoir à propos de…

10100

Federal Register / Vol. 86, No. 31 / Thursday, February 18, 2021 / Notices
jbell on DSKJLSW7X2PROD with NOTICES

Convention on Psychotropic Substances of 1971. CUMYL-PEGACLONE has no therapeutic use, and its use constitutes a substantial risk to public health.
The committee recommended that CUMYL-PEGACLONE Chemical name: 5pentyl-2-2-phenylpropan-2-yl-2,5-dihydro1H-pyrido4,3-bindol-1-one, be added to Schedule II of the Convention on Psychotropic Substances of 1971.
MDMB-4en-PINACA
Substance Identification MDMB-4en-PINACA Chemical name:
methyl S-3,3-dimethyl-2-1-pent-4-en-1-yl1H-indazole-3-carboxamidobutanoate is a synthetic cannabinoid. It has been identified in seized material formulated for smoking, and found as white to yellow/brown powder.
WHO Review History MDMB-4en-PINACA has never been formally reviewed by WHO and is not currently under international control.
Information was brought to WHOs attention that this substance is clandestinely manufactured, poses a risk to public health, and has no recognized therapeutic use.
Similarity to Known Substances and Effects on Central Nervous System MDMB-4en-PINACA is a synthetic cannabinoid that binds to CB1 cannabinoid receptors as a full and potent agonist. It is structurally similar to 5F-MDMB-PINACA
5F-ADB which is controlled under Schedule II of the Convention on Psychotropic Substances of 1971. A report from an unpublished animal study indicates that MDMB-4en-PINACA can produce the characteristic effects of CB1 cannabinoid agonists such as hypothermia and lethargy.
Reports from online user forums describe cannabis-like euphoria at moderate levels of intake, with dissociation described at higher doses. Both sedation and stimulation have been reported, in addition to memory loss, confusion and agitation.
Dependence Potential No animal or human studies were identified that described the dependence potential of MDMB-4en-PINACA. As a full CB1 agonist, it would be expected to produce dependence similar to other CB1 receptor agonists.
Actual Abuse and/or Evidence of Likelihood of Abuse No animal or human studies have been conducted to provide an indication of the likelihood of abuse of MDMB-4en-PINACA, though CB1 receptor agonists have known abuse potential. A number of countries across different regions have reported MDMB-4enPINACA use. Its use has been associated with cases of impaired driving and death.
Therapeutic Usefulness MDMB-4en-PINACA is not known to have any therapeutic use.
Recommendation MDMB-4en-PINACA Chemical name:
methyl S-3,3-dimethyl-2-1-pent-4-en-1-yl1H-indazole-3-carboxamidobutanoate is a potent synthetic cannabinoid receptor agonist with a similar mechanism of action,
VerDate Sep<11>2014

17:47 Feb 17, 2021

Jkt 253001

and similar effects to a number of other synthetic cannabinoids that are controlled under Schedule II of the Convention on Psychotropic Substances of 1971. Use of MDMB-4en-PINACA has been associated with severe adverse effects, including fatal intoxications, and cases of impaired driving.
MDMB-4en-PINACA has no therapeutic use.
The Committee recommended that MDMB-4en-PINACA Chemical name:
methyl S-3,3-dimethyl-2-1-pent-4-en-1-yl1H-indazole-3-carboxamidobutanoate be added to Schedule II of the Convention on Psychotropic Substances of 1971.
3-methoxyphencyclidine 3-MeO-PCP
Substance Identification 3-methoxyphencyclidine 3-MeO-PCP, Chemical name: 1-1-3methoxyphenylcyclohexylpiperidine is an arylcyclohexylamine and 3-methoxy derivative of phencyclidine PCP which is controlled under Schedule II of the Convention on Psychotropic Substances of 1971. It appears as powder and tablets.
WHO Review History 3-methoxyphencyclidine has never been formally reviewed by WHO and is not currently under international control.
Information was brought to WHOs attention that this substance is clandestinely manufactured, poses a risk to public health, and has no recognized therapeutic use.
Similarity to Known Substances and Effects on Central Nervous System 3-methoxyphencyclidine is an N-methyl-Daspartate NMDA receptor antagonist with a similar mechanism of action and effects to phencyclidine. These effects include an altered mental state characterized by confusion, disorientation and out of body experiences as well as hallucinations and other psychotic symptoms.
Dependence Potential No human or animal studies have examined the dependence potential of 3methoxyphencyclidine.
Actual Abuse and/or Evidence of Likelihood of Abuse As an NMDA receptor antagonist, 3methoxyphencyclidine would be expected to produce similar effects, and have abuse potential similar to that of phencyclidine.
Adverse effects include cardiovascular effects such as hypertension and tachycardia and cognitive effects including psychosis, confusion and agitation. There may be a greater risk of psychosis in those with a history of, or vulnerability to psychotic illness. Cases of severe and fatal intoxication are reported from several countries and regions.
Seizures have been reported in a number of countries from several different regions.
Therapeutic Usefulness 3-methoxyphencyclidine is not known to have any therapeutic use.
Recommendation 3-methoxyphencyclidine Chemical name:
1-1-3-methoxyphenylcyclohexyl piperidine is an analogue of, and has similar effects to phencyclidine PCP, which is
PO 00000

Frm 00067

Fmt 4703

Sfmt 4703

controlled under Schedule II of the 1971
Convention on Psychotropic Substances. Its mode of action suggests a likelihood of abuse.
There is evidence of use of this substance in a number of countries across different regions. 3-methoxyphencyclidine causes substantial harm, including severe adverse events such as hallucinations, other psychotic symptoms, and fatal intoxications.
It has no therapeutic use.
The Committee recommended that 3methoxyphencyclidine Chemical name: 1-13-methoxyphenylcyclohexylpiperidine be added to Schedule II of the Convention on Psychotropic Substances of 1971.
Diphenidine Substance Identification Diphenidine Chemical name: 1-1,2diphenylethylpiperidine is a dissociative and hallucinogenic substance of the 1,2diarylethylamine class. It appears as powder and tablets.
WHO Review History Diphenidine has never been formally reviewed by WHO and is not currently under international control. Information was brought to WHOs attention that this substance is clandestinely manufactured, poses a risk to public health, and has no recognized therapeutic use.
Similarity to Known Substances and Effects on Central Nervous System Diphenidine is known to produce hallucinogenic and dissociative effects through its action as an N-methyl-D-aspartate NMDA receptor antagonist. This mechanism of action as well as its effects are similar to those of phencyclidine PCP
which is controlled under Schedule II of the 1971 Convention on Psychotropic Substances.
Dependence Potential No animal or human studies have determined the dependence potential for diphenidine.
Actual Abuse and/or Evidence of Likelihood of Abuse As an NMDA receptor antagonist, diphenidine would be expected to have abuse potential similar to that of phencyclidine. In addition, diphenidine causes dopamine release, in a manner similar to, but to a lesser degree, than cocaine. This effect may also contribute to its abuse potential.
Cases of intoxication requiring hospitalization are reported. Adverse effects include cardiovascular effects such as tachycardia and hypertension and central nervous system effects including hallucinations, depersonalization, delusions, paranoia, dissociation, confusion, nystagmus and muscle rigidity. These effects have resulted in cases of acute intoxication leading to emergency department admissions. A
small number of fatal intoxications involving diphenidine have been documented. All deaths involved multiple drug toxicity, though cardiovascular and hallucinogenic symptoms described in the cases are consistent with the effects of diphenidine.
Seizures have been reported in a number of countries from several different regions.

E:FRFM18FEN1.SGM

18FEN1